Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
Group medical visits for addressing weight and blood pressure in an underserved population
These factors have led to the ADA/EASD recommendation that GLP-1 RAs be the preferred first injectable glucose-lowering agent for T2D (ahead of insulin therapy
Nutrition, protein intake, hydration, resistance training, sleep improvement, and regular monitoring remain important parts of long-term success
References: (1) Nauck MA et al
In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease
